Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Clin Pathol. 2014 Sep;142(3):313-9. doi: 10.1309/AJCPDTTL2I5ECMFG.

Mesothelin expression in pancreatic mucinous cysts.

Author information

1
From the Departments of Pathology and Laboratory Medicine and.
2
Department of Pathology, University of Alabama at Birmingham.
3
Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia; and.
4
From the Departments of Pathology and Laboratory Medicine and jhalan@uphs.upenn.edu.

Abstract

OBJECTIVES:

Mesothelin (MSLN) is a differentiation antigen found to be overexpressed in intraductal papillary mucinous neoplasms (IPMNs) and is a potential treatment target in pancreatic ductal adenocarcinoma.

METHODS:

From institutional archives, 114 cases of resected pancreatic mucinous cysts were identified, including IPMN and mucinous cystic neoplasm (MCN). Immunohistochemical analysis of MSLN was performed on representative sections.

RESULTS:

MSLN was seen more frequently in neoplastic epithelial cells from IPMN (39/52; P < .0005) and MCN (9/14; P < .0001) compared with unremarkable adjacent pancreatic and bile ducts (0/57) and benign foveolar and duodenal epithelium (0/21). When present, MSLN was diffusely expressed in neoplastic epithelium and only focally expressed in adjacent ducts (8/57). No significant difference was seen (P = .26) in MLSN expression between IPMN (79%) and MCN (83%) when only presence or absence was considered.

CONCLUSION:

Our findings suggest that MLSN can be used as a marker of neoplastic transformation of epithelial cells in pancreatic mucinous cysts. The findings can help identify neoplastic mucinous epithelium.

KEYWORDS:

Mesothelin; Mucinous cysts; Pancreas

PMID:
25125620
DOI:
10.1309/AJCPDTTL2I5ECMFG
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center